Strong Response to SARS-CoV-2 Vaccine Additional Doses among Patients with Inflammatory Bowel Diseases
Public Deposited- Creator
-
Long, M. D.
- Affiliation: School of Medicine, Department of Medicine
-
Weaver, K. N.
- Affiliation: School of Medicine, Department of Medicine
-
Zhang, X.
- Affiliation: School of Medicine, Department of Pediatrics
-
Chun, K.
- Other Affiliation: LabCorp
-
Kappelman, M. D.
- Affiliation: School of Medicine, Department of Pediatrics
- PREVENT-COVID Study Group
- Abstract
- The SARS-CoV-2 pandemic has disrupted health care and has resulted in high mortality rates. Vaccination is an international priority to mitigate the risks of SARS-CoV-2. The initial trials for development of SARS-CoV-2 vaccines excluded individuals with immunocompromising conditions. As individuals on immunosuppression, including those with inflammatory bowel diseases (IBD), may not mount as robust an antibody titer to vaccination, the Food and Drug Administration (FDA) has recommended an additional dose after the initial series.
- Date of publication
- 2022
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association
- Language
- English
- Version
- Postprint
- ISSN
- 1542-7714
Relations
- Parents:
- In Collection:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
Strong_Response_to_SARS-CoV-2_Vaccine.pdf | 2022-03-01 | Public | Download |